Show simple item record

FieldValueLanguage
dc.contributor.authorTang, Min-Moonen_AU
dc.contributor.authorFok, Jie Shenen_AU
dc.contributor.authorThong, Bernard Yu-Horen_AU
dc.contributor.authorYun, Jamesen_AU
dc.contributor.authorLi, Philip Heien_AU
dc.contributor.authorKang, Hye-Ryunen_AU
dc.contributor.authorThien, Francisen_AU
dc.contributor.authorYamaguchi, Masaoen_AU
dc.contributor.authorLucas, Michaelaen_AU
dc.contributor.authorChang, Yoon-Seoken_AU
dc.contributor.authorKim, Byung-Keunen_AU
dc.contributor.authorNagao, Mizuhoen_AU
dc.contributor.authorRengganis, Irisen_AU
dc.contributor.authorTsai, Yi-Giienen_AU
dc.contributor.authorChung, Wen-Hungen_AU
dc.contributor.authorRerkpattanapipat, Tichaen_AU
dc.contributor.authorKamchaisatian, Wasuen_AU
dc.contributor.authorLeung, Ting Fanen_AU
dc.contributor.authorHo, Joo-Yoonen_AU
dc.contributor.authorZhang, Luoen_AU
dc.contributor.authorLatiff, Amir Hamzah Abdulen_AU
dc.contributor.authorFujisawa, Takaoen_AU
dc.contributor.authorCastells, Mariana Cen_AU
dc.contributor.authorDemoly, Pascalen_AU
dc.contributor.authorWang, Jiu Yaoen_AU
dc.contributor.authorPawankar, Rubyen_AU
dc.date.accessioned2020-12-21
dc.date.available2020-12-21
dc.date.issued2020en_AU
dc.identifier.urihttps://hdl.handle.net/2123/24226
dc.description.abstractBackground: The issues and challenges in the diagnosis of drug allergy/hypersensitivity among children and adults in Asia are likely to be different from non-Asian countries. Objective: To study the diagnostic modalities used in the evaluation and management of drug allergy/drug hypersensitivity reactions (DHRs) among member societies of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Methods: A questionnaire comprising 41 questions was circulated electronically to member societies and individual members of APAAACI between January 23, 2020 and March 6, 2020. Results: Twenty-six respondents from 15 member societies and 1 individual member responded. European DHR guidelines were most commonly used. Skin prick and intradermal testing was used by 100%, with only 60% having access to commercial penicillin skin test reagents. In vitro-specific IgE tests were used by 75%, and basophil activation test by 56.3% for immediate DHR. Patch tests were used by 75% in contrast to lymphocyte transformation tests by 25% for nonimmediate DHR. Drug provocation tests were used by 68.8%, the most common indication being to exclude hypersensitivity where history/symptoms were not suggestive of drug hypersensitivity/allergy (93.3%). Human leukocyte antigen (HLA) genotype testing was mandatory among 25% respondents before new carbamazepine prescriptions, and 8.3% for allopurinol prescriptions. Conclusions: There was increased use of skin testing for iodinated contrast media hypersensitivity and patch testing for nonimmediate DHR. HLA genotype testing prior to new carbamazepine, allopurinol and abacavir prescriptions remain variable despite strong associations for severe cutaneous adverse reactions with Asian ethnicity. Results of this survey form a useful framework for developing educational and training needs and for improving access to drug allergy diagnostic and treatment modalities across APAAACI member societies.en_AU
dc.language.isoenen_AU
dc.subjectCOVID-19en_AU
dc.subjectCoronavirusen_AU
dc.titleDiagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countriesen_AU
dc.typeArticleen_AU
dc.identifier.doi10.5415/apallergy.2020.10.e36


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.